Effect of Risedronate on Osteoblast Differentiation, Expression of Receptor Activator of NF-κB Ligand and Apoptosis in Mesenchymal Stem Cells

Hirofumi Fujita, Kazuko Kurokawa, Tetsuya Ogino, Mio Ono, Masanao Yamamoto, Takashi Oka, Tohru Nakanishi, Naoya Kobayashi, Noriaki Tanaka, Tomohiro Ogawa, Etsuko Suzaki, Kozo Utsumi, Junzo Sasaki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Nitrogen-containing bisphosphonates (BPs) are antiresorptive drugs used for the treatment of metabolic bone diseases. Bone marrow stromal cells such as mesenchymal stem cells (MSCs) and MSC-derived osteoblasts that originate from MSCs are known to regulate osteoclast differentiation and activation via the expression of receptor activator of NF-κB ligand (RANKL). Although the effects of nitrogen-containing BPs on osteoclasts and osteoblasts have been well investigated, their effects in MSCs have not been clarified. In this study, we investigated the effects of risedronate (RIS), a nitrogen-containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC-derived osteoblasts. The RANKL expression induced by 1,25-(OH) 2 vitamin D 3 was not affected by RIS in human MSC-derived osteoblasts. In addition, treatment with high-concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS-induced chromatin condensation was suppressed by a pan-caspase inhibitor zVAD-FMK and a cell-permeable isoprenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis and suggest that the antiresorptive effect of RIS is not mediated by a decrease in the RANKL expression in MSC-derived osteoblasts.

Original languageEnglish
Pages (from-to)78-84
Number of pages7
JournalBasic and Clinical Pharmacology and Toxicology
Volume109
Issue number2
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Osteoblasts
Stem cells
Mesenchymal Stromal Cells
Apoptosis
Ligands
Diphosphonates
Nitrogen
Terpenes
Osteoclasts
Chromatin
Condensation
Bone
Integrin-Binding Sialoprotein
Bone Density Conservation Agents
Risedronate Sodium
Caspase Inhibitors
Cholecalciferol
Osteocalcin
Differentiation Antigens
Metabolic Bone Diseases

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Effect of Risedronate on Osteoblast Differentiation, Expression of Receptor Activator of NF-κB Ligand and Apoptosis in Mesenchymal Stem Cells. / Fujita, Hirofumi; Kurokawa, Kazuko; Ogino, Tetsuya; Ono, Mio; Yamamoto, Masanao; Oka, Takashi; Nakanishi, Tohru; Kobayashi, Naoya; Tanaka, Noriaki; Ogawa, Tomohiro; Suzaki, Etsuko; Utsumi, Kozo; Sasaki, Junzo.

In: Basic and Clinical Pharmacology and Toxicology, Vol. 109, No. 2, 08.2011, p. 78-84.

Research output: Contribution to journalArticle

Fujita, Hirofumi ; Kurokawa, Kazuko ; Ogino, Tetsuya ; Ono, Mio ; Yamamoto, Masanao ; Oka, Takashi ; Nakanishi, Tohru ; Kobayashi, Naoya ; Tanaka, Noriaki ; Ogawa, Tomohiro ; Suzaki, Etsuko ; Utsumi, Kozo ; Sasaki, Junzo. / Effect of Risedronate on Osteoblast Differentiation, Expression of Receptor Activator of NF-κB Ligand and Apoptosis in Mesenchymal Stem Cells. In: Basic and Clinical Pharmacology and Toxicology. 2011 ; Vol. 109, No. 2. pp. 78-84.
@article{84f41e4a6da14e85b588e472dbb6eeae,
title = "Effect of Risedronate on Osteoblast Differentiation, Expression of Receptor Activator of NF-κB Ligand and Apoptosis in Mesenchymal Stem Cells",
abstract = "Nitrogen-containing bisphosphonates (BPs) are antiresorptive drugs used for the treatment of metabolic bone diseases. Bone marrow stromal cells such as mesenchymal stem cells (MSCs) and MSC-derived osteoblasts that originate from MSCs are known to regulate osteoclast differentiation and activation via the expression of receptor activator of NF-κB ligand (RANKL). Although the effects of nitrogen-containing BPs on osteoclasts and osteoblasts have been well investigated, their effects in MSCs have not been clarified. In this study, we investigated the effects of risedronate (RIS), a nitrogen-containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC-derived osteoblasts. The RANKL expression induced by 1,25-(OH) 2 vitamin D 3 was not affected by RIS in human MSC-derived osteoblasts. In addition, treatment with high-concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS-induced chromatin condensation was suppressed by a pan-caspase inhibitor zVAD-FMK and a cell-permeable isoprenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis and suggest that the antiresorptive effect of RIS is not mediated by a decrease in the RANKL expression in MSC-derived osteoblasts.",
author = "Hirofumi Fujita and Kazuko Kurokawa and Tetsuya Ogino and Mio Ono and Masanao Yamamoto and Takashi Oka and Tohru Nakanishi and Naoya Kobayashi and Noriaki Tanaka and Tomohiro Ogawa and Etsuko Suzaki and Kozo Utsumi and Junzo Sasaki",
year = "2011",
month = "8",
doi = "10.1111/j.1742-7843.2011.00685.x",
language = "English",
volume = "109",
pages = "78--84",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Effect of Risedronate on Osteoblast Differentiation, Expression of Receptor Activator of NF-κB Ligand and Apoptosis in Mesenchymal Stem Cells

AU - Fujita, Hirofumi

AU - Kurokawa, Kazuko

AU - Ogino, Tetsuya

AU - Ono, Mio

AU - Yamamoto, Masanao

AU - Oka, Takashi

AU - Nakanishi, Tohru

AU - Kobayashi, Naoya

AU - Tanaka, Noriaki

AU - Ogawa, Tomohiro

AU - Suzaki, Etsuko

AU - Utsumi, Kozo

AU - Sasaki, Junzo

PY - 2011/8

Y1 - 2011/8

N2 - Nitrogen-containing bisphosphonates (BPs) are antiresorptive drugs used for the treatment of metabolic bone diseases. Bone marrow stromal cells such as mesenchymal stem cells (MSCs) and MSC-derived osteoblasts that originate from MSCs are known to regulate osteoclast differentiation and activation via the expression of receptor activator of NF-κB ligand (RANKL). Although the effects of nitrogen-containing BPs on osteoclasts and osteoblasts have been well investigated, their effects in MSCs have not been clarified. In this study, we investigated the effects of risedronate (RIS), a nitrogen-containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC-derived osteoblasts. The RANKL expression induced by 1,25-(OH) 2 vitamin D 3 was not affected by RIS in human MSC-derived osteoblasts. In addition, treatment with high-concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS-induced chromatin condensation was suppressed by a pan-caspase inhibitor zVAD-FMK and a cell-permeable isoprenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis and suggest that the antiresorptive effect of RIS is not mediated by a decrease in the RANKL expression in MSC-derived osteoblasts.

AB - Nitrogen-containing bisphosphonates (BPs) are antiresorptive drugs used for the treatment of metabolic bone diseases. Bone marrow stromal cells such as mesenchymal stem cells (MSCs) and MSC-derived osteoblasts that originate from MSCs are known to regulate osteoclast differentiation and activation via the expression of receptor activator of NF-κB ligand (RANKL). Although the effects of nitrogen-containing BPs on osteoclasts and osteoblasts have been well investigated, their effects in MSCs have not been clarified. In this study, we investigated the effects of risedronate (RIS), a nitrogen-containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC-derived osteoblasts. The RANKL expression induced by 1,25-(OH) 2 vitamin D 3 was not affected by RIS in human MSC-derived osteoblasts. In addition, treatment with high-concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS-induced chromatin condensation was suppressed by a pan-caspase inhibitor zVAD-FMK and a cell-permeable isoprenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis and suggest that the antiresorptive effect of RIS is not mediated by a decrease in the RANKL expression in MSC-derived osteoblasts.

UR - http://www.scopus.com/inward/record.url?scp=79960231913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960231913&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2011.00685.x

DO - 10.1111/j.1742-7843.2011.00685.x

M3 - Article

C2 - 21332944

AN - SCOPUS:79960231913

VL - 109

SP - 78

EP - 84

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 2

ER -